February 6, 2019 - Page 23 of 23

NASDAQ Companies - February 6, 2019

Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan

Out-licensing of commercialization rights allows for significant operating expense savings Upfront payments improve near-term liquidity VANCOUVER, British Columbia, Feb. 06, […]

NYSE Companies - February 6, 2019

Equinor ASA: Informasjon angående foreslått utbytte for fjerde kvartal 2018

Nøkkelinformasjon vedrørende foreslått kontantutbytte for Equinor (OSE: EQNR, NYSE:EQNR) for fjerde kvartal 2018. Utbyttebeløp: 0,26 Annonsert valuta: USD Siste dag […]

NYSE Companies - February 6, 2019

Equinor ASA: Information relating to proposed dividend for fourth quarter 2018

Key information relating to the proposed cash dividend to be paid by Equinor (OSE:EQNR, NYSE:EQNR) for fourth quarter 2018. Proposed […]

NYSE Companies - February 6, 2019

Equinor fourth quarter 2018 and year end results

Equinor (OSE: EQNR, NYSE: EQNR) reports adjusted earnings of USD 4.4 billion and USD 1.5 billion after tax in the […]

NYSE Companies - February 6, 2019

Equinors resultater for fjerde kvartal og året 2018

Equinor (OSE: EQNR, NYSE: EQNR) rapporterer et justert driftsresultat på 4,4 milliarder USD og 1,5 milliarder USD etter skatt i […]

NASDAQ Companies - February 6, 2019

Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering

AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops […]